Stockscreener 앱 받기
7.80
6.56%
0.48
시장 영업 전:
7.80
Immunitybio Inc 주식(IBRX)의 최신 뉴스
Price to book forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Shareholders to Connect - ACCESS Newswire
Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller - Insider Monkey
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IMMP) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
ImmunityBio, Inc. (NASDAQ:IBRX): Are Analysts Optimistic? - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect - ACCESS Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
ImmunityBio | 4: Statement of changes in beneficial ownership of securities-Director Selecky Christobel - Moomoo
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026 - Insider Monkey
ImmunityBio (IBRX) director awarded 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director Wesley Clark receives 65,600 stock options at $7.25 strike - Stock Titan
ImmunityBio (IBRX) director granted 65,600 stock options at $7.25 strike - Stock Titan
Director at ImmunityBio (NASDAQ: IBRX) awarded 65,600 options - Stock Titan
ImmunityBio (IBRX) re-elects full board, ratifies Deloitte as 2026 auditor - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
2026-06-09 | Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Stockholders to Inquire about Securities Investigation | NDAQ:IMMP | Press Release - Stockhouse
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
FDA to Review Expanded Use of Cancer Drug - Los Angeles Business Journal
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend - Stocktwits
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc.: Shareholders Board Members Managers and Company Profile | US45256X1037 - marketscreener.com
ImmunityBio Inc Cash Flow – XETR:26CA - TradingView
ImmunityBio director Simon Barry J. sells $165,305 in stock - Investing.com UK
Director Barry Simon Sells 23,033 Shares of ImmunityBio Inc (IBR - GuruFocus
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny - Investing.com
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now - Yahoo Finance
ImmunityBio director Simon Barry J. sells $165,305 in stock By Investing.com - Investing.com India
ImmunityBio (IBRX) director Simon sells 23,033 shares under Rule 10b5-1 plan - Stock Titan
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio responds to FDA promotional compliance concerns - Investing.com
ImmunityBio stock rises after FDA compliance response - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors - TipRanks
IBRX: ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications - TradingView
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
0.45%
5.59%
자본화:
|
볼륨(24시간):